The Journal for Nurse Practitioners
Volume 3, Issue 6 , Pages 393-403 , June 2007

Hodgkin Lymphoma: An Update

  • Ellen Mullen, RN, ANP, GNP

      Affiliations

    • Ellen Mullen, RN, ANP, GNP, works in the Lymphoma and Myeloma Department of the MD Anderson Cancer Center in Houston, Texas.
    • ,
  • Yazhen Zhong, RN, ANP, AOCNP

      Affiliations

    • Yazhen Zhong, RN, ANP, AOCNP, also works in the Lymphoma/Myeloma Department of the MD Anderson Cancer Center in Houston, Texas.

References 

  1. MacMahon B . Epidemiology of Hodgkin's disease . Cancer Res . 1966;26:1189–1200
  2. American Cancer Society  . Cancer facts and figures 2006 . Available at: www.cancer.org Accessed December 3, 2006.
  3. Surveillance Epidemiology End Results (SEER). Cancer stat fact sheets: Hodgkin's lymphoma. Available at: seer.cancer.gov/statfacts. Accessed December 3, 2006.
  4. Rosdahl N , Larson SO , Clemmesen J . Hodgkin's disease in patients with previous infectious mononucleosis: 30 years' experience . Br Med J . 1974;2(5913):253–256
  5. Hjalgrim H , Askling J , Sorensen P , et al.   Risk of Hodgkin's disease and other cancers after infectious mononucleosis . J Natl Cancer Inst . 2000;92(18):1522–1528
  6. Weiss LM , Movahed LA , Warnke RA , et al.   Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease . N Engl J Med . 1989;320(8):502–506
  7. Pallesen G , Hamilton-Dutoit SJ , Rowe M , et al.   Expression of Epstein-Barr virus latent gene products in tumor cells in Hodgkin's disease . Lancet . 1991;337(8737):320–322
  8. Jarrett RF . Viruses and Hodgkin's lymphoma . Ann Oncol . 2002;13(S1):23–29
  9. Jarrett RF , Armstrong AA , Alexander E . Epidemiology of EBV Hodgkin's lymphoma . Ann Oncol . 1996;7(suppl):S5–S10
  10. Goedert JJ , Cote TR , Virgo P , et al.   Spectrum of AIDS-associated malignant disorders . Lancet . 1998;351(9119):1833–1839
  11. Franceschi S , Dal Maso L , La Vecchia C . Advances in the epidemiology of HIV-associated non-Hodgkin's lymphoma and other lymphoid neoplasms . Int J Cancer . 1999;83(4):481–485
  12. Grulich AE , Wan X , Law MG , Coates M , Kaldor JM . Risk of cancer in people with AIDS . AIDS . 1999;13(7):839–843
  13. Clifford GM , Polesel J , Rickenbach M , et al.   Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy . J Natl Cancer Inst . 2005;97(6):425–432
  14. Cheung MC , Pantanowitz L , Dezube BJ . AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy . Oncology . 2005;10(6):412–426
  15. Engels EA , Pfeiffer RM , Goedert JJ , et al.   Trends in cancer risk among people with AIDS in the United States 1980-2002 . AIDS . 2006;20(12):1645–1654
  16. Benharroch D , Shemer-Avni Y , Myint YY , et al.   Measles virus: evidence of an association with Hodgkin's disease . Br J Cancer . 2004;91(3):572–579
  17. Gutensohn N , Cole P . Childhood social environment and Hodgkin's disease . N Engl J Med . 1981;304(3):135–140
  18. Alexander FE , Rickette TJ , McKinney PA , Cartwright RA . Community life style characteristics and incidence of Hodgkin's disease in young people . Int J Cancer . 1991;48(1):10–14
  19. Chang ET , Zheng T , Weir EG , et al.   Childhood social environment and Hodgkin's lymphoma: new findings from a population based case control study . Cancer Epidemiol Biomarkers Prev . 2004;13(8):1361–1370
  20. Landgren O , Engels EA , Pfeiffer RM , et al.   Autoimmunity and susceptibility to Hodgkin's lymphoma: a population-based case-control study in Scandinavia . J Natl Cancer Inst . 2006;98(18):1321–1330
  21. Ishibe N , Tucker M . Epidemiology of Hodgkin's and non-Hodgkin's lymphomas . In:  Canettos GP ,  Lister TA ,  Young B editor. The lymphomas . 2nd ed.. Philadelphia, PA: Saunders Elsevier; 2006;p. 127
  22. Cozen W , Gill PS , Ingles SA , et al.   IL-6 levels and genotype are associated with risk of young adult Hodgkin's lymphoma . Blood . 2004;103(8):3216–3221
  23. Thomas RK , Re D , Wolf J , et al.   Part I: Hodgkin's lymphoma–molecular biology of Hodgkin's and Reed-Sternberg cell . Lancet Oncol . 2004;5(1):11–18
  24. Brauninger A , Schmitz R , Bechtel D , et al.   Mini review: molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma . Int J Cancer . 2005;118(8):1853–1861
  25. Weinshel EL , Peterson BA . Hodgkin's disease . CA: Cancer J Clin . 1993;43(6):327–372
  26. Baetz T , Belch A , Couban A , et al.   Gemcitabine, dexamethasone, and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group . Ann Oncol . 2003;14(12):1762–1767
  27. Re D , Kuppers R , Diehl V . Molecular pathogenesis of Hodgkin's lymphoma . J Clin Oncol . 2005;23(26):6379–6386
  28. Mathas S , Lietz A , Anagnostopoulos I , et al.   c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis . J Exp Med . 2004;199(8):1041–1052
  29. Khan G . Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? . Exp Hematol . 2006;34(4):399–406
  30. Marafioti et al.
  31. Harris NL , Jaffe ES , Stein H , et al.   A revised European-American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group . Blood . 1994;84(5):1361–1392
  32. Feldman AL , Pittaluga S , Jaffe ES . Classification and histopathology of the lymphomas . In:  Canellos GP ,  Lister TA ,  Young B editor. The lymphomas . 2nd ed.. Philadelphia, PA: Saunders Elsevier; 2006;p. 2
  33. Lister TA , Crowther D , Sutcliffe SB , et al.   Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting . J Clin Oncol . 1989;7(11):1630–1636
  34. Yahalom J , Straus D . Hodgkin's lymphoma . In:  Pazdur R ,  Coia LR ,  Hoskins WJ ,  Wagman LD editor. Cancer management: a multidisciplinary approach . 9th ed.. Lawrence, KS: CMP Healthcare Media; 2005;p. 675
  35. Hasenclever D , Diehl V . A prognostic score for advanced Hodgkin's disease . N Engl J Med . 1998;339(21):1506–1514
  36. Van Spronsen DJ , Veldhuis GJ . New development in staging and follow-up of patients with Hodgkin's lymphoma . Neth J Med . 2003;61(9):278–283
  37. Ekstrand BC , Horning SJ . Hodgkin's disease . Blood Rev . 2002;16(2):111–117
  38. Meyer RM , Ambinder RF , Stroobants S . Hodgkin's lymphoma: evolving concepts with implications for practice . Hematology Am Soc Hematol Educ Program . 2004;184–202
  39. Hutchings M , Loft A , Hansen M , et al.   FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin's lymphoma . Blood . 2006;107(1):52–59
  40. Rueda A , Olmos D , Viciana R , et al.   Treatment for relapse in stage I/II Hodgkin's lymphoma after initial single-modality treatment . Clin Lymphoma Myeloma . 2006;6(5):389–393
  41. NCCN Clinical Practice Guidelines in Oncology V. 1. (2006). Hodgkin's Disease/Lymphoma.
  42. Yazbeck V , Georgakis G , Wedgwood A , et al.   Hodgkin's lymphoma: molecular targets and novel treatment strategies . Future Med . 2006;2(4):533–551
  43. Zinzani PL , Magagnoli M , Frezza G , et al.   ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease . Leuk Lymphoma . 1999;32(5-6):553–559
  44. Zheng B , Georgakis GV , Li Y , et al.   Introduction of cell-cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin's disease cell lines is independent of inhibitor of NF-kB mutations or activations of CD30, CD40 and RANK receptors . Clin Cancer Res . 2004;10(9):3207–3215
  45. Younes A , Pro B , Fayad L . Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin's lymphoma [letter] . Blood . 2006;107(4):1731a–1732a
  46. Takayama S , Reed JC , Homma S . Heat-shock proteins as regulators of apoptosis . Oncogene . 2003;22(56):9041–9047
  47. Georgakis GV , Younes A . Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond . Future Oncol . 2005;1(2):273–281
  48. Vose JM , Constine LS , Sutcliffe SB . Other complications of the treatment of Hodgkin's disease . In:  Mauch PM ,  Armitage JO ,  Diehl V editor. Hodgkin's disease . London, United Kingdom: Lippincott Williams and Wilkins; 1999;p. 661–671

 Author has financial relationships with business or industry to disclose.

PII: S1555-4155(07)00293-0

doi: 10.1016/j.nurpra.2007.04.006

The Journal for Nurse Practitioners
Volume 3, Issue 6 , Pages 393-403 , June 2007

Article Tools

* Image Usage & Resolution